Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Zanidatamab (zani) in previously treated HER2+ biliary tract cancer (BTC): Impact on patient-reported pain outcomes in the phase 2b HERIZON-BTC-01 study.
Authors
Shubham Pant
The University of Texas MD Anderson Cancer Center, Houston, TX
Shubham Pant , Jia Fan , Do-Youn Oh , Hye Jin Choi , Jin Won Kim , Heung-Moon Chang , Lequn Bao , Hui-Chuan Sun , Teresa Macarulla , Feng Xie , Jean-Philippe Metges , Jie-Er Ying , John A Bridgewater , Mohamedtaki Abdulaziz Tejani , Emerson Yu-sheng Chen , Harpreet Singh Wasan , Michel Pierre Ducreux , Jiafang Ma , Phillip M. Garfin , James J. Harding
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Clinical Trial Registration Number
NCT04466891
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 450)
DOI
10.1200/JCO.2024.42.3_suppl.450
Abstract #
450
Poster Bd #
A15
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
A phase IIb, open-label, single-arm study of zanidatamab (ZW25) monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers.
First Author: Shubham Pant
Poster
2024 ASCO Annual Meeting
Zanidatamab in previously-treated HER2-positive (HER2+) biliary tract cancer (BTC): Overall survival (OS) and longer follow-up from the phase 2b HERIZON-BTC-01 study.
First Author: Shubham Pant
Poster
2021 Gastrointestinal Cancers Symposium
Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study.
First Author: Funda Meric-Bernstam
Poster
2023 ASCO Annual Meeting
Trastuzumab (T) plus gemcitabine-cisplatin (GC) for treatment naïve HER2 positive biliary tract adenocarcinomas (BTC): A multicentre open-label, phase II study (TAB).
First Author: Vikas S. Ostwal